← All indications
Cholangiocarcinoma
A malignant tumor arising from the epithelium of the BILE DUCTS.
Subtype terms (1)
More specific conditions that are subtypes of Cholangiocarcinoma in the MeSH hierarchy.
- Klatskin Tumor
23 drugs (18 approved, 5 experimental)
Drugs by status
Approved for this indication (3)
Phase 4 trials (13)
Phase 3 trials (27)
- atezolizumab
- irinotecan
- paclitaxel
- lapatinib
- nivolumab
- pembrolizumab
- n-butyl-2-cyanoacrylate
- methylene blue
- ipilimumab
- carboplatin
- s-1
- bortezomib
- cytokine induced killer cells
- gimeracil
- oteracil
- cisplatin
- tegafur
- ivosidenib
- etoposide
- melphalan
- levoleucovorin
- toripalimab
- bintrafusp alfa
- tislelizumab
- Tinengotinib
- [f-18]fapi-74
- ctx-009
Phase 2 trials (150)
- sd-101
- decitabine
- azacitidine
- heparin
- abemaciclib
- anlotinib
- allogeneic natural killer cells
- autologous tumor infiltrating lymphocytes
- avelumab
- olaparib
- urea
- sorafenib
- Amcasertib
- venetoclax
- binimetinib
- ceritinib
- cobimetinib
- devimistat
- silmitasertib
- donafenib
- doxorubicin
- durvalumab
- e7090
- entinostat
- entrectinib
- erdafitinib
- famitinib
- fimaporfin
- olutasidenib
- trametinib
- +120 more
Phase 1 trials (68)
- merestinib
- ly-3023414
- Fosgemcitabine
- afatinib
- cdx-301
- tofacitinib
- dkn-01
- ds-1001b
- guadecitabine
- imiquimod
- lmb-100
- margetuximab
- pegph20
- personalized neoantigen vaccine
- pneumococcal 13-valent conjugate vaccine
- qrh-882260
- ephb4-hsa fusion protein
- ricolinostat
- stp705
- taladegib
- autologous dendritic cells
- rabeprazole
- trk-950
- tucatinib
- cea car-t cells
- incb062079
- adh-1
- sildenafil
- obi-833
- ly-3039478
- +38 more
Organizations
Organization Involved with Phase 4 Indications (18)
- Cheju Halla General Hospital
- Hospital General Universitario Gregorio Marañon
- Seoul National University
- Tokyo Medical and Dental University
- Universidad de Murcia
- University of Valencia
- University Alicante
- University of Barcelona
- Universidad Autonoma de Barcelona
- Hospital Clinico Lozano Blesa
- Humboldt University
- Nutricia
- Hospital Universitario Ntra. Sra. de La Candelaria
- Autonomous University of Madrid
- Vall d'Hebron Institute of Research, Galatea Clinic
- Fundación para la Investigación Biomédica del Hospital 12 de Octubre
- HOSPITAL UNIVERSITARIO VIRGEN DEL ROCIO, SEVILLA
- HOSPITAL UNIVERSITARIO MARQUES DE VALDECILLA, SANTANDER
Organization Involved with Phase 3 Indications (54)
- Incyte
- Merck Serono
- Eli Lilly
- Merck KGaA
- Hengrui Therapeutics, Inc.
- Sirtex Medical
- Agios Pharmaceuticals, Inc.
- Otsuka
- The Christie NHS Foundation Trust
- National Cancer Institute (NCI)
- University of Pittsburgh
- Canadian Cancer Trials Group
- Cancer Research Campaign
- Cancer Research UK
- Center Eugene Marquis
- Centre Georges Francois Leclerc
- University of London
- Cornell University
- Harvard University
- Eastern Hepatobiliary Surgery Hospital
- Federation Francophone de Cancerologie Digestive
- Deutsche Krebshilfe e.V.
- NRG Oncology
- Southwest Oncology Group
- The First People's Hospital of Changzhou
- University of Hamburg
- UNICANCER
- University of Louisville
- University of Toronto
- Xinjiang Medical University
- +24 more
Organization Involved with Phase 2 Indications (153)
- Abbott
- Boston Biomedical
- Daiichi Sankyo
- Eisai
- Celgene
- Shire
- Bristol-Myers Squibb
- Servier
- Roche
- AstraZeneca
- Merck
- Exelixis
- Genentech
- Plexxikon
- Genzyme
- Pfizer
- Sanofi
- Sanofi-Synthelabo
- Ipsen
- AIO-Studien-gGmbH
- Novartis
- ArQule
- Bayer
- BIND Therapeutics
- Criterium, Inc.
- Dong-A Pharmaceutical
- FeRx
- GlaxoSmithKline
- Hannover Clinical Trial Center GmbH
- Medivir
- +123 more
Organization Involved with Phase 1 Indications (35)
- Seattle Genetics
- Fennec Pharma
- Celldex Therapeutics
- Halozyme Therapeutics
- Leap Therapeutics, Inc.
- Sirnaomics
- Toray Industries, Inc
- Boehringer Ingelheim
- Translational Drug Development
- Academic and Community Cancer Research United
- Akita University
- Duke University
- University of Washington
- University of Nebraska
- University of Cincinnati
- Vanderbilt University
- Loxo Oncology
- Xencor
- City of Hope National Medical Center
- University of North Carolina at Chapel Hill
- University of Tokyo
- Department of Veteran Affairs
- ICON
- National Comprehensive Cancer Network
- Novotech
- Vasgene Therapeutics, Inc
- Van Andel Research Institute
- Government of Poland
- Antengene Corporation
- Celon Pharma SA
- +5 more
Organization Involved with Other Experimental Indications (9)